Guangdong Zhongsheng Pharmaceutical (SHE:002317) received supplementary approval from China's National Medical Products Administration for an additional dosage of fenofibrate capsules, according to a Saturday filing with the Shenzhen bourse.
The drug company added a 0.2-gram specification for the high cholesterol capsules, it said in its disclosure.
Shares in the pharmaceutical company rose 2% during afternoon trading on Monday.